IPA modulates host NAD+ salvage via aryl hydrocarbon receptor–SIRT1 axis to drive sex‑specific longevity effects

Hypothesis

Circulating indole-3-propionic acid (IPA) extends lifespan and improves musculoskeletal health by activating the aryl hydrocarbon receptor (AhR) in intestinal epithelial cells, which upregulates the NAD+ salvage enzyme NAMPT and subsequently increases SIRT1 deacetylase activity. This cascade reduces oxidative stress and cellular senescence, but its magnitude depends on sex‑dependent AhR expression modulated by estrogen signaling.

Mechanistic Rationale

1. AhR activation by IPA – IPA is a known ligand for AhR. AhR activation in gut epithelium induces transcription of Nampt, boosting intracellular NAD+ levels.
2. NAD+–SIRT1 link – Elevated NAD+ enhances SIRT1 activity, promoting deacetylation of p53, FOXO, and NF‑κB, thereby lowering senescence-associated secretory phenotype (SASP) and oxidative stress.
3. Sex specificity – Estrogen receptor‑α (ERα) antagonizes AhR transcriptional activity. In females with high endogenous estrogen, AhR‑driven Nampt induction is blunted, limiting NAD+ rise. Males or ovariectomized females show stronger AhR response, explaining genotype‑ and sex‑specific effects observed in Drosophila and mice.
4. Microbiome‑host interface – The abundance of the fldC gene (encoding the IPA‑synthesizing enzyme) predicts serum IPA (r=0.80) [1]. Thus, individuals with high fldC‑carrying taxa should exhibit higher AhR activation, NAD+, and SIRT1 activity.

Testable Predictions

• Prediction 1: In aged male mice, oral IPA supplementation will increase hepatic NAD+ concentrations and SIRT1 activity by ≥30% relative to vehicle, accompanied by improved grip strength and extended median lifespan. The same intervention in aged female mice will produce <10% changes unless mice are ovariectomized or treated with an ERα antagonist.
• Prediction 2: In a human cohort, plasma IPA levels will positively correlate with plasma NAD+ metabolites (nicotinamide, nicotinamide riboside) and SIRT1 activity in peripheral blood mononuclear cells (PBMCs) after adjusting for age, sex, and fldC‑gene abundance in stool metagenomes.
• Prediction 3: Administering an AhR antagonist (e.g., CH-223191) alongside IPA will abolish the NAD+ and SIRT1 elevation and negate any functional benefits in male mice, confirming pathway dependence.

Experimental Design (outline)

1. Animal study – Use 20‑month‑old C57BL/6J mice (n=15 per sex per group). Groups: vehicle, IPA (10 mg/kg/day), IPA+AhR antagonist, IPA+ERα antagonist (females only). Measure serum IPA, hepatic NAD+, SIRT1 activity, grip strength, frailty index, and survival over 12 months.
2. Human observational study – Recruit 300 adults aged 50‑80, stratified by sex. Collect fasting blood, stool, and dietary records. Quantify IPA (LC‑MS/MS), NAD+ metabolomics, SIRT1 activity (acetyl‑p53 ELISA), and stool fldC abundance (qPCR). Use multivariable regression to test IPA‑NAD+ association.
3. Intervention pilot – Give 50 mg IPA daily for 12 weeks to 40 participants with low baseline IPA (<10 µM) and high fldC abundance. Pre/post measurements of NAD+, SIRT1 activity, and cognitive‑physical composite scores.

Falsifiability

If IPA supplementation fails to raise NAD+ or SIRT1 activity in male mice, or if IPA levels do not predict NAD+ metabolites in humans after controlling for fldC abundance, the proposed AhR‑NAD+‑SIRT1 mechanism is refuted. Similarly, if AhR blockade does not attenuate IPA‑induced benefits, the hypothesis loses support.

Implications

Confirming this pathway would position IPA not merely as a biomarker but as a modulatable metabolite that links gut microbiome composition to host redox and epigenetic regulation via NAD+ biology. It would also justify sex‑stratified trials and guide microbiome‑targeted interventions for age‑related decline.